NHS Framework Agreement for the supply of Recombinant Factor IX products for the treatment of Haemophilia B NHS England Closes 11th December

Invitation to offer for NHS Framework Agreement for the supply of Recombinant Factor IX products for the treatment of Haemophilia B. Period of framework agreement: 1st March 2019 to 28th February 2021 with options to extend up to a further 24 months. Total maximum framework agreement including extension options will be no more than 48 months.

Find out more >>>

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.